Individuals who used GLP-1RAs for 0.5, 1, and 1.5 years had IRRs close to 1.0, with no significant decrease in MACE risk at three years, although these estimates varied across specific treatment strategies defined by prior duration and subsequent exposure patterns
They can assess whether the symptom is related to the medication, an underlying condition, or another cause entirely
Support groups, online and in-person, provide room for open discussion, advice, and solace
One of the most common concerns we hear at Blue Horizon relates to the thyroid: can semaglutide cause thyroid issues, and if you already have a thyroid condition, is it safe to use
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity